TOP TEN perturbations for 1221_at (Homo sapiens)

Organism: Homo sapiens
Gene: 1221_at
Selected probe(set): 201276_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 1221_at (201276_at) across 6673 perturbations tested by GENEVESTIGATOR:

B-CLL study 11 (DMSO) / vehicle (DMSO) treated normal B-cell sample

Relative Expression (log2-ratio):1.9918251
Number of Samples:4 / 4
Experimental B-CLL study 11 (DMSO)
Peripheral blood mononuclear cells (PBMCs) obtained from chronic lymphocytic leukemia (CLL) patients and in vitro treated with vehicle (DMSO) for 4 hours. PBMCs’ samples contained 90% CD19+ CD5+ B lineage CLL cells (B-CLL). Inclusion criteria: untreated CLL patients or at least 1 month after chemotherapy. Exclusion criteria: patients with active infections or other serious medical conditions or with white blood cell (WBC) counts of 15,000/l.
Control vehicle (DMSO) treated normal B-cell sample
MACS purified resting B-cells from healthy donor peripheral blood treated with vehicle (DMSO) for 4 hours.

R547 study 1 (24h) / vehicle (DMSO) treated DU145 cell sample

Relative Expression (log2-ratio):-1.9290533
Number of Samples:2 / 4
Experimental R547 study 1 (24h)
Human prostate carcinoma metastatic cell line DU145 treated with the CDK inhibitor R547 [4-amino-2-(1-methanesulfonylpiperidin-4-ylamino) pyrimidin-5-yl]-(2, 3-difluoro-6-methoxyphenyl)methanone (Hoffmann-La Roche compound) for 24 hours at a 3xIC90 concentration of 5.1 μmol/L. ATC code:---
Control vehicle (DMSO) treated DU145 cell sample
Human prostate carcinoma metastatic cell line DU145 treated with vehicle (DMSO) for 24 hours.

bone cancer study 1 (PDX; chondrosarcoma, NOS; primary) / bone cancer study 1 (PDX; myxoid chondrosarcoma; primary)

Relative Expression (log2-ratio):-1.716116
Number of Samples:2 / 2
Experimental bone cancer study 1 (PDX; chondrosarcoma, NOS; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary chondrosarcoma, NOS of the bone (subcutaneously implanted).
Control bone cancer study 1 (PDX; myxoid chondrosarcoma; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary myxoid chondrosarcoma of the bone (subcutaneously implanted).

bone cancer study 1 (PDX; chondroblastic osteosarcoma; primary) / bone cancer study 1 (PDX; myxoid chondrosarcoma; primary)

Relative Expression (log2-ratio):-1.7013779
Number of Samples:2 / 2
Experimental bone cancer study 1 (PDX; chondroblastic osteosarcoma; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary chondroblastic osteosarcoma of the bone (subcutaneously implanted).
Control bone cancer study 1 (PDX; myxoid chondrosarcoma; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary myxoid chondrosarcoma of the bone (subcutaneously implanted).

B-CLL study 11 (rolipram) / rolipram study 4 (normal B-cell; 20uM)

Relative Expression (log2-ratio):1.6514254
Number of Samples:4 / 4
Experimental B-CLL study 11 (rolipram)
Peripheral blood mononuclear cells (PBMCs) obtained from chronic lymphocytic leukemia (CLL) patients and in vitro treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. PBMCs’ samples contained 90% CD19+ CD5+ B lineage CLL cells (B-CLL). Inclusion criteria: untreated CLL patients or at least 1 month after chemotherapy. Exclusion criteria: patients with active infections or other serious medical conditions or with white blood cell (WBC) counts of 15,000/l. ATC code:---
Control rolipram study 4 (normal B-cell; 20uM)
MACS purified resting B-cells from healthy donor peripheral blood treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. ATC code:---

R547 study 3 (24h) / vehicle (DMSO) treated DU145 cell sample

Relative Expression (log2-ratio):-1.6364288
Number of Samples:3 / 4
Experimental R547 study 3 (24h)
Human prostate carcinoma metastatic cell line DU145 treated with the CDK inhibitor R547 [4-amino-2-(1-methanesulfonylpiperidin-4-ylamino) pyrimidin-5-yl]-(2, 3-difluoro-6-methoxyphenyl)methanone (Hoffmann-La Roche compound) for 24 hours at an IC90 concentration of IC90 = 1.7 μmol/L. ATC code:---
Control vehicle (DMSO) treated DU145 cell sample
Human prostate carcinoma metastatic cell line DU145 treated with vehicle (DMSO) for 24 hours.

PIPKIa depletion study 1 (siRNA) / control siRNA transfected HEK293 cell sample

Relative Expression (log2-ratio):1.593029
Number of Samples:3 / 3
Experimental PIPKIa depletion study 1 (siRNA)
HEK293 cells were transfected with siRNA specific for PIPKIalpha.
Control control siRNA transfected HEK293 cell sample
HEK293 cells were transfected with control siRNA.

idiopathic pulmonary fibrosis study 9 (contractile; ribo. bound RNA) / idiopathic pulmonary fibrosis study 9 (contractile; total RNA)

Relative Expression (log2-ratio):1.5857754
Number of Samples:6 / 6
Experimental idiopathic pulmonary fibrosis study 9 (contractile; ribo. bound RNA)
Primary lung myofibroblasts explanted from patients with idiopathic pulmonary fibrosis (IPF) grown in a 3-dimensional type I collagen matrix and allowed to contract. Tissues were obtained from IPF patients (age range 57-68 years) at the time of biopsy, autopsy, lung resection or lung transplantation. Primary cells outgrowth were cultured in DMEM growth medium (10% FCS) and passaged at a 1:4 split ratio until passage 4 to 9. Cells were considered myofibroblasts if they had a typical spindle morphology, if they were vimentin- and alpha smooth muscle actin-positive and factor VIII and surfactant C-negative. To simulate the environment of physiological healing, the 3-dimensional type I collagen gel was released from the border of the dish to allow primary cells to freely contract (contractile matrices). Microarray was performed only with ribosome-bound RNA.
Control idiopathic pulmonary fibrosis study 9 (contractile; total RNA)
Primary lung myofibroblasts explanted from patients with idiopathic pulmonary fibrosis (IPF) grown in a 3-dimensional type I collagen matrix and allowed to contract. Tissues were obtained from IPF patients (age range 57-68 years) at the time of biopsy, autopsy, lung resection or lung transplantation. Primary cells outgrowth were cultured in DMEM growth medium (10% FCS) and passaged at a 1:4 split ratio until passage 4 to 9. Cells were considered myofibroblasts if they had a typical spindle morphology, if they were vimentin- and alpha smooth muscle actin-positive and factor VIII and surfactant C-negative. To simulate the environment of physiological healing, the 3-dimensional type I collagen gel was released from the border of the dish to allow primary cells to freely contract (contractile matrices). Microarray was performed with total RNA.

colorectal cancer study 4 (recurring) / adjacent colon tissue (recurring)

Relative Expression (log2-ratio):-1.5743332
Number of Samples:24 / 3
Experimental colorectal cancer study 4 (recurring)
LCM-tumor tissue samples of patients who received resection after diagnosis of primary colorectal cancer. Patients developed metastatic recurrence during follow-up after surgery.
Control adjacent colon tissue (recurring)
Histologically normal colon tissue samples from patients with primary colorectal cancer collected after resection. Tissue was further extracted using laser-capture microdissection (LCM). With metastatic recurrence after resection during follow-up.

renal cell carcinoma study 10 (PDX; clear cell adenocarcinoma, NOS; metastatic) / renal cell carcinoma study 10 (PDX; clear cell adenocarcinoma, NOS; primary)

Relative Expression (log2-ratio):-1.5727844
Number of Samples:2 / 18
Experimental renal cell carcinoma study 10 (PDX; clear cell adenocarcinoma, NOS; metastatic)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from a metastasis of patients with primary clear cell adenocarcinoma, NOS of the kidney (subcutaneously implanted). Metastatic site of patient tumor sample is not reported.
Control renal cell carcinoma study 10 (PDX; clear cell adenocarcinoma, NOS; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary clear cell adenocarcinoma, NOS of the kidney (subcutaneously implanted).